Seagen and LAVA Therapeutics ink $700M+ deal for EGFR solid tumor platformBusiness, TherapeuticsSeagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million. Read more September 26, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/08/brain-scans.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-09-26 10:37:352022-09-26 10:37:35Seagen and LAVA Therapeutics ink $700M+ deal for EGFR solid tumor platform
